Results 251 to 260 of about 5,450,952 (343)

Short peptide perturbs spermatogenesis via immune microenvironment dysregulation and mitochondrial imbalance

open access: yesFEBS Open Bio, EarlyView.
In the blood–testis barrier, occludin is crucial for tight junctions. This study demonstrates that occludin‐targeting short peptides disrupt junction integrity, inducing immune cell infiltration, tumor necrosis factor‐α/interleukin‐6 secretion and mitochondrial dysfunction, ultimately triggering apoptosis.
Heng Wang, Xiaofang Tan, Deyu Chen
wiley   +1 more source

Identifying prognostic targets in metastatic prostate cancer beyond AR

open access: yesFEBS Open Bio, EarlyView.
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng   +13 more
wiley   +1 more source

Current trends in single‐cell RNA sequencing applications in diabetes mellitus

open access: yesFEBS Open Bio, EarlyView.
Single‐cell RNA sequencing is a powerful approach to decipher the cellular and molecular landscape at a single‐cell resolution. The rapid development of this technology has led to a wide range of applications, including the detection of cellular and molecular mechanisms and the identification and introduction of novel potential diagnostic and ...
Seyed Sajjad Zadian   +6 more
wiley   +1 more source

Preparation and characterization of renal cell peptides from fetal rats for their antitumor activity

open access: yesFEBS Open Bio, EarlyView.
This study aimed to prepare renal cells (RCs) from fetal rats which were digested by enzymes. Candidate peptides RCPs were characterized by capillary HPLC and MS and their bioactivity was predicted using peptideranker. The predicted top 10 bioactive peptides were synthesized.
Zhe Zhang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy